Carlat Publishing

Carlat Publishing offers healthcare professionals straightforward and engaging psychiatric education that is free from bias. We aim to deliver actionable information, enabling clinicians to quickly implement what they learn to improve their daily practice and deliver top-notch care to their patients.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#292994

United States

#75570

Health/Mental Health

#201

Traffic sources

Monthly visitors

Articles

Psych Meds that Cause Weight Loss? Yes, They Exist.

4 days ago | thecarlatreport.com | Daniel Carlat

GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know. In the May issue of The Carlat Psychiatry Report, Dr. Chris Aiken reviews psychotropics that can lead to weight loss. For seasoned clinicians, some may be familiar—but the value here is having them all in one place, with clinical nuance.
You Work in the Inpatient Unit, and You Probably Don't Do Enough Therapy

4 days ago | thecarlatreport.com | Daniel Carlat

When patients are acutely psychotic, manic, or suicidal, our impulse is to fine tune the meds. But a few years ago—while working primarily inpatient—I realized I was leaning too heavily on medication. My patients needed more. Then I came across a powerful framework by Michelle Stein and Michelle Jacobo that reframed how I think about inpatient therapy.
A new AI tool can spot tardive dyskinesia (TD) more accurately than trained clinicians.

1 week ago | thecarlatreport.com | Daniel Carlat

TD affects ~2.6 million people in the U.S., but only 40,000 are being treated We now have effective meds—valbenazine was approved in 2017—but the bigger challenge is detection Clinicians are told to use the AIMS at every visit, yet many don’t feel confident using it (or don’t use it at all) This new video-based tool uses AI to flag TD from short patient clips—even outside the clinic It caught TD with 82% sensitivity and 82% specificity, outperforming trained human raters It works across age,...
When “Education” Is Really Strategy: A Closer Look at Lilly’s Alzheimer’s CME

1 week ago | thecarlatreport.com | Daniel Carlat

I just read a Lilly-sponsored CME on Medscape featuring Dr. Malaz Boustani—a respected geriatrician doing critical work with underserved communities. But this isn't just education—it's marketing for Lilly’s anti-amyloid drug Donabemab. Link: https://lnkd.in/evwta6p8Here’s what Lilly is really doing:Amplifying the Problem:“99% miss early MCI diagnosis.”This frames clinicians as falling short—and primes them for the solution Lilly will offer.
You Can Be Neurodivergent. And Still Need Care.

2 weeks ago | thecarlatreport.com | Daniel Carlat

At Carlat Publishing, we regularly debate trends in psychiatry—and neurodivergence is one of today’s most charged topics. Let’s call it opinion divergence: Some on our team feel that the DSM-5 term “autism spectrum disorder” is politically insensitive. Others see it as clinically essential. That conversation got me thinking: How did we get to a place where a diagnosis is considered offensive?
Antidepressant Oddities | CARLAT PUBLISHING

2 weeks ago | thecarlatreport.com | Daniel Carlat

Talia Puzantian and I are in the thick of revising the Medication Fact Book, 8th edition—slated for release this fall. I’m currently working on the antidepressants chapter, and one of our favorite parts of the book is adding “fun facts” to the end of each medication. They’re strange, surprising, and oddly memorable. Here are a few that stood out:Selegiline (Emsam)Emsam was named after “Emily” and “Samuel,” the children of the Somerset Pharmaceuticals CEO.
Benzos: Misunderstood, Misused - but Sometimes Just Right.

2 weeks ago | thecarlatreport.com | Daniel Carlat

"The only thing that works for me is Xanax.""Can I get a 3-month script for Klonopin? My last doc didn't mind."We’ve all heard versions of these. They often trigger concern—or judgment. But behind these quotes are patients trying to manage real distress. And many of us lack a consistent, evidence-based framework beyond “use extreme caution.”Benzos are fast, effective, and generally well-tolerated. They’re overused in some groups, underused in others.
FDA Clears First Alzheimer's Blood Test—What's Actually New Here?

2 weeks ago | thecarlatreport.com | Daniel Carlat

This week, the FDA cleared the first blood test for Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio. It sounds like a big step forward. Maybe it will prove to be one. But after 22 years of Carlat Report coverage of overhyped tests and treatments, I’ve learned to pause before celebrating “firsts.”Let’s unpack what this test actually offers—and where the clinical utility starts to fray.
Choosing ADHD Meds: A 3 Minute Overview

2 weeks ago | thecarlatreport.com | Daniel Carlat

ADHD pharmacology can feel overwhelming. Dozens of formulations. Conflicting data. High stakes for outcomes—and side effects. Each chapter of our Medication Fact Book starts with general tips, and I’m revising the ADHD section for our 8th edition. Here’s the ultra Cliff Notes version:Stimulants vs non-stimulantsStimulants are more effective—unless there’s a reason not to use them. Viloxazine may have a faster onset than atomoxetine, but it’s still pricey.
Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

2 months ago | thecarlatreport.com | Daniel Carlat |Talia Puzantian

Now including app access!We are pleased to announce a new online app version of the Medication Fact Book to use on your smartphone for rapid access whenever you need it. It's designed to look up med info quickly while seeing patients. All versions of your book purchase include (for free) access to this new resource. Take a sneak peek at how the app works in this short YouTube video.